Basal-Like Phenotype in a Breast Carcinoma Case Series from Sudan: Prevalence and Clinical/Pathological Correlations by Awadelkarim, Khalid Dafaallah et al.
SAGE-HindawiAccess to Research
Pathology Research International
Volume 2011, Article ID 806831, 10 pages
doi:10.4061/2011/806831
Research Article
Basal-LikePhenotype in aBreastCarcinoma CaseSeries from
Sudan:Prevalence andClinical/Pathological Correlations
KhalidDafaallahAwadelkarim,1 CarmeloArizzi,2 ElgizouliOmerMusaElamin,3
HusseinM. A.Hamad,3 PasqualeDe Blasio,4,5 SalwaO. Mekki,6 Ihsan Osman,3
Ida Biunno,5,7 Nasr EldinElwali,1,8 Massimo CostanzoBarberis,9
and RenatoMariani-Costantini10
1 Department of Molecular Biology, National Cancer Institute (NCI-UG), University of Gezira, P. O. Box 20, Hospital Street,
Wad Medani, Sudan
2 Servizio di Anatomia Patologica, Azienda Ospedaliera di Circolo di Melegnano, Via Pandina 1,
20070 Vizzolo Predabissi, Milan, Italy
3 Departments of Histopathology & Cytopathology and Oncology, Radiation & Isotope Centre Khartoum (RICK),
Algaser Street, P. O. Box 846, Khartoum, Sudan
4 Integrated Systems Engineering Srl., Via Fantoli 16/15, 20138 Milan, Italy
5 BioRep, Via Fantoli 16/15, 20138, Milan, Italy
6 National Health Laboratory, Federal Ministry of Health, P. O. Box 287, Khartoum, Sudan
7 Institute for Biomedical Technologies, National Research Council, Via Fratelli Cervi, 93, 20090 Segrate, Milan, Italy
8 Department of Basic Sciences, College of Medicine, Al Imam Mohamed Bin Saud Islamic University, P.O. Box 5701,
Riyadh 11432, Saudi Arabia
9 Department of Pathology, European Institute of Oncology, Via Ripamonti 435, 20141, Milan, Italy
10Department of Oncology and Experimental Medicine, “G. d’Annunzio” University and Unit of Molecular Pathology and Genomics,
Aging Research Center (CeSI), “G. d’Annunzio” University Foundation, Via Colle dell’Ara, 66013 Chieti, Italy
Correspondence should be addressed to Khalid Dafaallah Awadelkarim, awadelkarim@gmail.com
Received 11 September 2010; Accepted 24 November 2010
Academic Editor: Sunati Sahoo
Copyright © 2011 Khalid Dafaallah Awadelkarim et al. This is an open access article distributed under the Creative Commons
Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is
properly cited.
Basal-likebreast cancer, an aggressive subtype associated with high grade, poor prognosis,and younger age, is reported frequently
inAfrica.Weanalyzedtheexpressionofthebasalcytokeratins(CKs)5/6and17inacaseseriesfromCentralSudanandinvestigated
correlations among basal CK status, ER, PgR, and Her-2/neu, and individual/clinicopathological data. Of 113 primary breast
cancers 26 (23%), 38 (34%), and 46 (41%) were, respectively, positive for CK5/6, CK17, and combined basal CKs (CK5/6 and/or
CK17). Combined basal CK+ status was associated with higher grade (P<. 03) and inversely correlated with ER (P<. 002), PgR
(P = .004) and combined ER and/or PgR (P<. 0002). Two clusters based on all tested markers were generated by hierarchical
cluster analysis and k-mean clustering: I: designated “hormone receptors positive/luminal-like” and II: designated “hormone
receptors negative”, including both basal-like and Her-2/neu+ tumors. The most important factors for dataset variance were ER
status, followed by PgR, CK17, and CK5/6 statuses. Overall basal CKs were expressed in a fraction of cases comparable to that
reported for East and West African case series. Lack of associations with age and tumor size may represent a special feature of
basal-like breast cancer in Sudan.
1.Introduction
Cytokeratins (CKs) are used as diﬀerentiation markers in
breast cancer (BC), since their expression is thought to
remain stable in carcinogenesis [1]. In breast ducts CK8 and
CK18 are expressed in the luminal layer whereas CK5/6,
CK14, and CK17 characterize the basal layer [2–4]. Thus
BC may be luminal or basal with regard to CK phenotype,
with some tumors coexpressing both basal and luminal CKs
[2].Thisissupportedbymicroarray expressionproﬁlingthat2 Pathology Research International
classiﬁes BC into ﬁve prognostically and clinically relevant
molecular subtypes, luminal A, luminal B, basal-like, Her-
2/neu, and normal breast-like [5–16]. Accordingly, BC can
no longer be viewed as a single biologic and pathologic
entity, which implies a need for stratiﬁed rather than uniﬁed
approaches for research, prevention, and treatment [17].
The basal-like subtype overlaps, but is not synonymous,
with the triple negative subset, which includes BCs that
do not express ER, PgR, and Her-2/neu and tend to
occur at a younger age and in patients with pathogenetic
BRCA1 mutations [18–21]. Approximately 85% of the ER–
/Her-2/neu– BCs are of basal-like phenotype [9]. Most
importantly,althoughmostbasal-likeBCsdonotexpressER,
PgR, or Her-2/neu, in case series of diﬀerent origin 14% to
45%ofthecaseswere reported to expressat leastone ofthese
markers [7, 9, 14].
Basal-like/triple negative BCs initially respond to
chemotherapy in the neoadjuvant setting, but their overall
prognosis remains poor [14]. Importantly, the tumors with
worst prognosis seem to be those expressing basal CKs [5, 7,
8, 22] or epidermal growth factor receptor (EGFR) [9, 23].
Basal-like BCs show common as well as heterogeneous
morphologic,genetic,andimmunophenotypicfeatures,and,
up to date, there is no international consensus regarding
their exact deﬁnition [5–12, 20]. Basal CKs, which have been
shown to be independently associated with poor outcome
[7, 9, 24–26], are expressed in most, but not all, BCs
classiﬁed as basal-like by immunohistochemical (IHC) or
gene microarray analysis [3, 7, 20, 27–29]. Furthermore
in a subset of BCs basal CKs are coexpressed with other
markers, including EGFR, P-cadherin, c-KIT, caveolin 1,
and p63, although consideration of such markers does not
appear to improve the identiﬁcation of the cases with poor
outcomecomparedtobasal CKsalone[20].Therefore Rakha
et al. [20] suggested to rely on basal CK expression alone
to deﬁne basal-like BC, remarking that, in spite of shared
clinicopathologic and IHC features, basal CK-positive BCs
and basal-like BCs are not strictly the same entity [7, 29].
Genetic, ethnic, and racial factors inﬂuence BC pheno-
types, possibly by determining intrinsic diﬀerences in tumor
biology [6, 30, 31]. In this regard, it is remarkable that
basal-like/triple negative BC appears to be more common
in African American women [6, 12, 32]a n di nB Cc a s e
series from West and East Africa (range: 22%–34%), where
it seems to be also associated with features indicative of poor
prognosis [33–36].
In a previous study we found that a BC case series from
Khartoum, Central Sudan, was comparable to one from
Milan,NorthernItaly,incombinedhormonereceptorsstatus
and BC subtypes [37]. Relative to the Italian patients, the
Sudanesepatientswereyoungerandtheirtumorswerelarger,
of higher grade and more advanced in stage [37].
We address here the question of the BC subtypes identi-
ﬁedbyclusteringanalyseswithintheSudaneseBCcaseseries.
To this end, we re-evaluated, using more sophisticated sta-
tistical analyses, the expression of the basal CKs 5/6 (CK5/6)
and17(CK17)inrelationtoestrogen/progesteronereceptors
(ER/PgR), human epidermal growth factor receptor 2 (Her-
2/neu), and the available clinicopathological and individual
Table 1: Basal cytokeratins in the studied case series.
Number (%)
CK5/6
Positive 26 (23)
Negative 87 (77)
CK17
Positive 38 (34)
Negative 75 (66)
Combined (CK5/6 and/or CK17)
Positive 46 (41)
Negative 67 (59)
Table 2: Basal breast cancer frequencies in the currently studied
case series, according to diﬀerent designations.
BC basal
subtype Designation Frequency
Basal CK+
basal CKs+ regardless of the
expression of other markers (basal
CK+)
46/113 (41%)
Basal-
like/triple-
negative
triple-negative
(ER−/PgR−/Her-2/neu−)
18/113 (15.9%)
Basal-like
triple-negative CK-positive proﬁle
(ER−/PgR−/Her-2/neu−/basal
CK+)
11/113 (10%)
data. We refer in this paper to two designations of BCs with
basal subtype: (i) basal CK+, deﬁning BCs that express basal
CKs regardless of the expression of other markers [20]a n d
(ii) basal-like, identiﬁed by thet r i p l e - n e g a t i v eC K - p o s i t i v e
proﬁle (ER−/PgR−/Her-2/neu−/basal CK+).
2.Materialsand Methods
2.1. Patients. The study is based on a series of 113 Sudanese
cases of primary invasive BC diagnosed between 2004-2005
at the Department of Histopathology & Cytopathology of
the Radiation and Isotope Center Khartoum (RICK), Khar-
toum, Sudan. This series, retrospectively selected to include
all consecutively accessioned BCs with available paraﬃn-
embedded material adequate for immunohistochemistry (as
determined by immunostaining with control antibodies),
was previously used to compare pathological, clinical, and
prognostic characteristics of BC in Sudan versus Italy [37].
Exclusion criteria were as follows: (a) in situ carcinomas,
(b) sarcomas, and (c) secondary tumors. Overall, the most
frequent histotype was invasive ductal carcinoma, which
accounted for 101/113 cases (89.4%). Other histotypes were
invasive lobular (5/113, 4.4%), mucinous (5/113, 4.4%),
medullary (1/113, 0.9%), and Paget’s (1/113, 0.9%). Some of
the included invasive ductal carcinomas were also associated
with other features: (i) inﬂammatory invasive ductal carci-
noma (1/113), (ii) lactating adenoma associated with inva-
siveductalcarcinoma (1/113),(iii)invasiveductalcarcinoma
with squamoid diﬀerentiation (1/113), and (iv) invasivePathology Research International 3
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Figure 1: Two clusters generated based on the statuses of basal cytokeratins (CK5/6, CK17), hormone receptors (ER, PgR), and Her-2/neu
by hierarchical cluster analysis ((a) & (b)) and k-mean clustering ((c) & (d)). Cases in each cluster are shown in (a) and (c). The factor(s)
that contribute to each cluster are shown in (b) and (d).
ductal carcinoma showing features of pleomorphic carci-
noma with cartilaginous diﬀerentiation(1/113).Histological
grading was performed using the Nottingham Combined
Histologic Grade (NCHG) system [38]. The breast tumors
included in this study were of intermediate grade (grade
2: 35/113; 31%) and high grade (grade 3: 78/113; 69%).
The intermediate-grade tumors included all the mucinous
carcinomas (5/5, 100%), 3 of the 5 lobular carcinomas (3/5,
60%), and 27/101(26.7%)of the invasive ductalcarcinomas.
On the other hand, the high-grade tumors included the
unique cases of Paget’s and medullary carcinomas and the
remaining invasive ductal carcinomas (74/101, 73.3%).
Age and tumor size were recorded only in 73 and 88
of the 113 cases, respectively. Most patients presented with
advanced disease and were lost to followup, as it frequently
occurs in developing countries [39–41]. Lack of data on
lymph nodestatusand follow upprecludedcorrelationswith
stage and prognosis [37]. According to data from the Sudan
Federal Ministry of Health, 78% of the Sudanese BC patients
have stage III or IV disease [42, 43].
2.2.Immunohistochemistry. Wholeconsecutivesectionswere
immunostained for ER (clone 1D5, Dako), PgR (clone PgR
636, Dako), Her-2/neu (polyclonal, Dako), CK5/6 (clone
D5/16 B4, Dako), CK17 (clone E3, Dako) and, as quality
controls of antigenic preservation, for the CK pool (clones
AE1–AE3, Dako) and vimentin (clone V9, Dako). IHC4 Pathology Research International
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Figure 2: (a) Score componentsofthree factors extracted forthe tested dataset variables.Factor analysisshowed thatthree factors explained
80.3% of the dataset variance. The ﬁrst factor extracted (eigenvalue = 2.1) accounted for the largest proportion of variance (42.3%) and
corresponded to hormone receptor status (with loads of ER: 0.80 and PgR: 0.78). The second factor (eigenvalue = 1.2) explained 23.4% of
variance and corresponded to basal cytokeratins status (with loads of CK17: 0.55 and CK5/6: 0.54). The third factor (eigenvalue = 0.7, with
a load of 0.6 forHer-2/neu status), a factor that explained 14.6% of the variance. (b) Individual factor scores of the three of the ﬁve extracted
factors. Note that some samples were superimposed. Factor scores were extracted by regression method.
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Figure 3: Scree plot of the eigenvalues. The adopted extraction
methods were theKaiser criterion,thatis,thesum ofsquared factor
loadings (eigenvalue) >1, and the scree test, that is, the place where
the smooth decrease of eigenvalues appears to level oﬀ to the right
of the plot of the eigenvalues.
results were recorded as percentages of immunostained cells
in ≥2000 neoplastic cells. Only nuclear reactivity was taken
intoaccountforERandPR,which wereclassiﬁedasnegative,
when absent or present in <5% of the neoplastic cells, or
positive, when present in ≥5% of the neoplastic cells. Only
intense and complete cell membrane immunoreactivity in
≥10% of the cells was taken as evidence of Her-2/neu over-
expression (score 3+) [44]. Borderline Her2/neu cases (score
2+) were reassessed by ﬂuorescence in situ hybridization
(FISH), as previously described [37]. Basal CKs 5/6 and 17
were regarded as positive when any cytoplasmic and/or cell
membrane staining was seen [6, 9, 37].
3.StatisticalAnalyses
Unsupervised hierarchical cluster analysis (CA) was done
for hormone receptors (ER, PgR), Her-2/neu and basal CK
(CK5/6 and/or CK17) statuses to determine the natural
clustering of the BCs according to the studied IHC markers.
CA was performed using squared Euclidean distance mea-
surements to obtain a dissimilarity matrix. Ward’s method
was then applied to this matrix to build a tree [45].
This method uses analysis of variance to evaluate distances
between clusters, minimizing the sum of squares of any two
hypothetical clusters that can be formed at each step. CA was
done using SPSS statistical package version 15.0 (SPSS Inc.,
Chicago, IL).
Unsupervised k-mean clustering algorithm, performed
with STATISTICA 7.0 (StatSoft, Inc., Tulsa, Ok), was applied
toconﬁrmand explore betterthe generated cluster(s).The k-
mean clustering used the Euclidean distance as the similarity
metric [46].
Data reduction was done by factor analysis, applying
principal components analysis (PCA) to the selected vari-
ables (ER, PgR, Her-2/neu, CK5/6, and CK17) to determinePathology Research International 5
Table 3: Basal cytokeratins status according to tumor grade, tumor
size (T), ER, PgR, combined ER/PgR, Her-2/neu, and histology.
CK5/6+ and/or CK17+, Number (%)
Positive Negative χ2
Grade
g2 9 (20) 26 (39) 4.72 (P<. 03)
g3 37 (80) 41 (61)
Tumor size (T)
T1 4( 9 ) 6( 9 )
0.67 (P = .88)
T2 21 (45.5) 25 (37)
T3 7 (15) 13 (19.5)
T4 5 (11) 7 (10.5)
NA¶ 9 (19.5) 16 (24)
ER
ER+ 21 (46) 50 (75) 9.8 (P<. 002)
ER− 25 (54) 17 (25)
PgR
PgR+ 23 (50) 51 (76) 8.2 (P = .004)
PgR− 23 (50) 16 (24)
Combined ER/PgR
ER+ and/or PgR+ 25 (54) 58 (87) 14.5 (P<. 0002)
ER−/PgR− 21 (46) 9 (13)
Her-2/neu
Her-2/neu+ 10 (22) 14 (21) 0.012 (P = .9)
Her-2/neu− 36 (78) 53 (79)
Histology
IDC∗ 45 (98) 56 (84%)
6.3 (P = .17)
ILC◦ —5 ( 7 % )
Mucinous 1( 2 ) 4( 6 % )
Medullary —1 ( 1 . 5 % )
Paget’s disease —1 ( 1 . 5 % )
¶NA: not available tumor size data in 25 cases, ∗IDC: inﬁltrating ductal
carcinoma, ◦ILC: inﬁltrating lobular carcinoma.
the minimum number of factors, among those considered,
that retained most of the dataset variance, and to quantify
the signiﬁcance of the explained variance for each variable
in dataset grouping(s). A scoring algorithm, that loaded
each individual variable most strongly onto the factor with
which it was most correlated, created summary factors. The
adopted extraction methods were the Kaiser criterion, that
is, the sum of squared factor loadings (eigenvalue) >1[ 47]
and the scree test, that identiﬁes the cut-oﬀ discriminating
important from unimportant factors in the plot of the
eigenvalues [48]. A default setting of 25 maximum iterations
of algorithm steps to obtain convergence was used to extract
factors. Factor scores were shown graphically. Statistical
analyses were developed by SPSS statistical package version
15.0 (SPSS Inc., Chicago, IL). Factor score loadings were
interpreted by rule of thumb in conﬁrmatory factor analysis
as follows: ≥0.7: higher factor; <0.7–≥0.6: high factor; <0.6–
≥0.4: central factor; <0.4–≥0.25: low factor; <0.25: lower
factors [49, 50]. Higher factors build on the rationale that
the 0.7 level corresponds to about half of the variance in the
indicator being explained by the factor. However, being the
0.7 standard high for real-life data, for exploratory purposes
lower levels were used, down to 0.7, with 0.4 for the central
factor and 0.25 for other factors [49, 50].
All cut-oﬀ values were determined before the statistical
procedures. Correlations between diﬀerent variables were
calculated using χ2 test or t-test. Signiﬁcance was set at <.05.
All P values were two-tailed.
4.Results
4.1. Immunohistochemical Characteristics and Basal Cytoker-
atin Status. Table 1 summarizes the basal cytokeratin status
in the studied case series. Of 113 primary BCs 26 (23%), 38
(34%), 18 (16%), and 46 (41%) were respectively positive
for CK5/6, for CK17, for CK5/6 and CK17, and for CK5/6
and/orCK17.The frequency ofthe basal CK+ subtype (basal
CKs+ regardless of other markers) was therefore 46/113
(41%), whereas the basal-like subtype as deﬁned by triple-
negative CK+ proﬁle (ER−/PgR−/Her-2/neu−/basal CK+)
was 11/113 (10%). Moreover, the frequency of basal-like
subtype as synonymous of triple negative, regardless of CK
status, was 18/113 (15.9%) (Table 2). Combined positive
basal CK status (CK5/6+ and/or CK17+) was associated
with higher grade (P<. 03, Table 3)a n dw a si n v e r s e l y
correlated with the expression of ER and PgR (resp., r =
−0.3, P<. 002; r =− 0.27, P = .004, Table 3). A highly
signiﬁcant negative correlation emerged when combined
hormone receptorstatus (ER+ and/or PgR+) was considered
(r =− 0.36, P<. 0002, Table 3).
There was no association between basal CK status and
Her-2/neu (Table 3). However, as basal CK+ status, Her-
2/neu+ status was inversely correlated with the expression
of ER and PgR (resp., r =− 0.27, P = .004; r =− 0.26,
P = .005), and with combined ER+ and/or PgR+ status
(r =− 0.28, P = .003). Basal CK status was not associated
with age at diagnosis (available for 73 cases) and tumor size
(available for 88 cases) (Tables 3 and 4); however, although
not signiﬁcant, the mean age of the patients with basal CK+
tumors was lower compared to that of the patients with
basal CK− tumors (49.8 ± 15.8 years versus 51.2 ± 14.1
years, Table 4), and the mean tumor size was smaller (4.5 ±
2.7cmversus5.4 ± 3.4cm,Table 4). All the lobular (5/113)
and mucinous tumors (5/113) were ER+/PgR+/Her-2/neu−
(luminal type) and all were negative for the basal CKs,
except one mucinoustumorthatwas found tobe positive for
CK5/6. The unique cases of Paget’s (1/113) and medullary
(1/113) carcinomas were both found to be ER−/PgR−/Her-
2/neu+/basal CK−(Her-2/neu subtype).
Therefore, the tumors positive for the basal CKs were
invasive duct carcinomas (98%), except a single mucinous
carcinoma (Table 3). No association emerged between basal
CKs expression and BC histotype (Table 3).
4.2. Cluster Distribution and Factor Analysis. Two major
clusters of patients were generated using hierarchical cluster
analysis (Figure 1(a)): cluster I with 65/113 (57.5%) patients6 Pathology Research International
Table 4: Basal cytokeratins status according to patient’s age at disease diagnosis and to tumor size.
CK5/6 and/or CK17
Positive Negative t-test
Age (years)∗
Mean ± SD¶ 49.8 ±15.85 1 .2 ±14.1( t = 0.57; P = .57; 95% CI −5.6–9.08)
Range 25–80 30–70
Mean tumor size (cm)#
Mean ± SD 4.5 ±2.75 .4 ±3.4( t = 0.58; P = .56; 95% CI −0.85 –1.55)
Range 1–15 1–14
∗The mean age of this series was 51.2 ± 14.3 years (range: 25–80 years), age was missing for 40 cases. ¶SD: standard deviation; #the mean tumor size of this
series was 4.7 ± 2.8cm (range: 1–15cm), size was missing for 25 cases.
Table 5: Component matrix of the ﬁve factors extracted by
principal component analysis (PCA).
Factor 1 Factor 2 Factor 3 Factor 4 Factor 5
ER 0.804 0.228 0.288 0.134 0.448
PgR 0.784 0.252 0.366 −0.015 −0.433
Her-2/neu −0.391 −0.678 0.612 0.112 0.012
CK5/6 −0.585 0.538 0.351 −0.488 0.080
CK17 −0.598 0.553 0.123 0.564 −0.051
and cluster II with 48/113 (42.5%) patients. Clustering the
ﬁve tested IHC markers revealed that hormone receptors
(ER, PgR) clustered in I whereas the basal CKs (CK 5/6,
CK 17, and Her-2/neu clustered in II, each in a separated
branch (Figure 1(b)). Hence, clusterI could be designated as
“hormonereceptorspositive/luminal-like,”whereasclusterII
as “hormone receptors negative,” including both the basal-
like and the Her-2/neu+ subtypes [5, 22, 26].
Comparable results were obtained through k-mean
clustering, with 72/113 (63.7%) patients joining cluster I
and 41/113 (36.3%) cluster II (Figure 1(c)). In addition k-
mean clustering revealed that hormone receptors (ER, PgR)
and basal CKs (CK 5/6, CK 17) played a major role in
identifying clusters I and II, respectively (Figure 1(d)). On
the other hand, Her-2/neu played quite similar roles in the
determination of the two clusters,with slightly higher weight
in cluster II (Figure 1(d)).
Factoranalysisshowedthatthreefactorsexplained80.3%
of the dataset variance (Figures 2(a) and 2(b)). The ﬁrst
factor(eigenvalue=2.1)accountedforthelargestproportion
of variance (42.3%) and corresponded to hormone receptor
status (loads: ER: 0.80; PgR: 0.78), while basal CKs (loads:
CK17: −0.6: CK5/6, −0.59) and Her-2/neu (load: −0.39)
statuses were negatively loaded on this factor. The second
factor (eigenvalue = 1.2) explained 23.4% of variance and
corresponded to basal CK status (loads: CK17, 0.55; CK5/6,
0.54),while Her-2/neustatus(load: −0.68)loaded negatively
on this factor. The third factor, corresponding to Her-2/neu
status (eigenvalue = 0.7, with a load of 0.6), explained 14.6%
o ft h ev a r i a n c e( Figure 2(a)). Individual factor scores of
the extracted factors are shown in Figure 2(b). Other two
factorsneededtobeextractedtoexplainthecompletedataset
variance, that is, factor 4, corresponding to CK17 status
(eigenvalue = 0.6, load: 0.56), that explained 11.7% of the
variance,whileCK5/6(load: −0.49)loadednegativelyonthis
factor and factor 5, corresponding to ER status (eigenvalue
= 0.4, load: 0.45), that explained 8% of the variance, while
PgR (load: −0.43) loaded negatively on this factor. The Scree
plot of the eigenvalues is shown in Figure 3.T h ec o m p o n e n t
matrix of these ﬁve factors is shown in Table 5.O fn o t e ,
these analyses are in support of the proposal of Rakha et
al. [20] who suggested to rely on basal CK expression alone
(basal CK+ subtype) to deﬁne basal-like BC, regardless of
the status of the other markers. In fact, our analyses assigned
all the BCs that expressed basal CKs, regardless of the other
markers, to cluster II. Furthermore, the basal-like subtype
(BCs with triple-negative phenotype that express basal CKs:
ER−/PgR−/Her-2/meu−/basal CKs+) was also included in
cluster II. It is worth mentioning that the adoption of the
lattercriteriononly for the deﬁnitionofbasal BCwould miss
many cases, as the basal-like subset accounted for only 10%
of the cases versus 41% for the basal CKs+ subset.
5.Discussion
The expression of basal CKs is a negative prognostic
marker, implying resistance to therapy and poor prognosis,
particularly in the context of BCs with triple-negative status
[12, 25, 26, 35, 51]. Basal-like BC, which largely overlaps
with triple-negative BC, is a well-recognized BC subtype
with the above-mentioned clinically-relevant implications
[12, 25, 26, 35, 51]. Basal-like/triple-negative BC appears to
occur more frequently in African American women and in
breast cancer case series from East and West Africa, which
could reﬂect intrinsic diﬀerences in tumor biology related to
racial/ethnic factors [6, 12, 21, 30, 32].
A better understanding of the impact of basal-like/triple
negative BC in BC series from native African women would
contribute to the assessment of the inﬂuence of race on this
particularly relevant BC subtype. It is important to develop
BCpreventionandtreatmentpoliciesinAfricanpopulations,
that, with increased life expectancy, are predicted to face
marked increases in BC rates [12, 14, 28, 35, 52, 53].
Recent studies found that the basal-like phenotype was
frequent in West (Nigeria and Senegal) and East (Uganda)
African BC case series (range: 22% to 27%), where it was
also associated with features of poor prognosis [33–36]. InPathology Research International 7
contrast, we [37]a n dA d e b a m o w oe ta l .[ 54] reported lower
frequencies of basal-like BC subtype (as deﬁned by triple-
negative, basal CK+ phenotype) in Sudanese (10%) and
Nigerian BC series (15.8%), which was mainly due to the
markedly higher frequency of hormone receptor positivity
found in these tumor series (Sudan: ER: 64%; PgR: 67%;
ER and/or ER: 75%, Nigeria: ER+: 65.1%; PgR: 54.7%), as
compared to the other studies from Africa [33–37, 54].
Consideration of two basal subtypes, that is, basal CK+,
deﬁned by expression of basal CKs regardless of other
markers [20], and basal-like, deﬁned by the triple-negative
CK+ phenotype (ER−/PgR−/Her-2/neu−/basal CK+), may
explain these discrepancies. In fact, in our BC series from
Central Sudan, the frequency of basal-like BC is 10%, as
previously reported [37] ,b u tt h a to fb a s a lC K +B Ci s4 1 % .
This reﬂects the presence of an excess of cases that express
basal CKs together with ER/PgR and/or Her-2/neu.
In the present Sudanese BC series the frequency of
basal CK+ status (41%) appears to be much higher than
those reported for Western Caucasian and also for African
American BC series (13–20% and 26%, resp.), but results
quite comparable to the 34% frequency found in a BC
series from Kyadondo County in Uganda and to the 33%
frequency reported from West Africa (Nigeria and Senegal)
[20, 25, 29, 33, 35, 51]. In the study of Adebamowo et al.,
basal CKs were not investigated and the basal-like subtype
was deﬁned by triple-negative phenotype only (ER−,P R −,
and Her-2/neu−)a so n ec a t e g o r y[ 54]. In this regard it is
notable that the Nigerian and the Sudanese case series yield
almost the same frequencies of basal-like BCs deﬁned by
triple negative phenotype only: 15.8%, that is, 24/152, in the
Nigerian series and 15.9%, that is, 18/113, in the Sudanese
series [37, 54].
In our Sudanese series, basal CK expression was associ-
atedwith higherhistologicgradeand with hormonereceptor
negative status. This is in agreement with well-established
evidence that the expression of basal markers occurs in
poorly diﬀerentiated hormone receptors-negative BCs, as
reported for Caucasian and African American series and also
fortheU gandanseries[25,26,35,51,55].Asinotherstudies,
CK17 was more frequently positive than CK5/6 [25].
It is well established that in both African-American
and Caucasian BC series the expression of basal CKs is
signiﬁcantly related to younger age at BC onset [26]. In
our Sudanese series basal CK status was not associated with
age at disease diagnosis, as also reported for the series from
Kyadondo County in Uganda [35]. However, although not
signiﬁcant,themeanageandthemeantumorsizewerelower
in the basal CK+ group than in the basal CK− one. The lack
ofsigniﬁcance for the diﬀerencein age may be due to the fact
that the patients were mostly young, reﬂecting the young age
atdisease diagnosis typicalof theinstitutionalBCseries from
the Sudan [37, 56–58].
Indeed, the higher frequency of basal-like phenotype
in African case series could be partially explained by the
younger age of the patients [33–36]. However, socioeco-
nomic, genetic, ethnic, and lifestyle/reproductive factors are
also likely to be involved [30, 37]. In particular, emerging
data reported that certainreproductivefactors (i.e.,extended
breast-feeding/lactation, high parity, and early menarche)
may have a greater impact on risk of certain molecular
BC subtypes compared to others [59, 60]. Furthermore,
other confounding factors, like antigen degradation of
archival formalin ﬁxed, paraﬃn-embedded tissue blocks,
should also be considered for the reportedly high frequency
of hormone receptor negativity, with subsequently higher
frequencies of both basal-like BC identiﬁed by the triple-
negative CK+ proﬁle (ER−/PgR−/Her-2/neu−/basal CK+)
a n du n c l a s s i ﬁ e dt r i p l e - n e g a t i v et y p e s[ 33, 36, 37, 54, 61].
The lack of association between basal CK+ status and
larger tumor size is quite unexpected [51]. This unusual
ﬁ n d i n gm i g h tr e ﬂ e c tt h ef a c tt h a tl a r g es i z ea tp r e s e n t a t i o n ,
due to late disease diagnosis, is one of the main features of
BC in Sudanese patients, when compared to BC in patients
from Europe and North America [9, 37, 62, 63]. Due to
longer survival, this could result in a relative enrichment of
less aggressive subtypesamong theBCsof largersize [37,64],
a hypothesis that requires to be further investigated in larger
and prognostically well-characterized BC series from Sudan.
Except one mucinous carcinoma, all the basal CK+
tumors were invasive duct carcinomas, consistent with the
literature data [51]. The fact that all the invasive lobular
tumors were basal CK− could be relevant but could also
reﬂect a bias due to the relatively low frequency of this
histotype in the study series and needs further evaluation on
al a r g e rn u m b e ro fc a s e s .
In concordance with the gene expression-based IHC
subtypes deﬁned in Western BC case series [5, 22, 26],
clustering based on the ﬁve tested IHC markers outlined
a hormone receptors-positive/luminal-like cluster and a
hormone receptors-negative cluster with basal CKs (CK5/6,
CK17) and Her-2/neu. As expected, factor analysis showed
that hormone receptor status was the factor that most
inﬂuenced dataset variance among the other tested factors,
being negatively aﬀected by both basal CK and Her-2/neu
statuses. Basal CK status was in second position, with Her-
2/neu status loaded negatively on this factor, although this
was not supported by a direct negative correlation. Her-
2/neu status was in the third place. The other two extracted
factors (factor 4: CK17 status, and factor 5: ER status) had
minimum eﬀectsas extracted factors on the dataset variance.
Collectively, this demonstrates that the most important
factors in the dataset were ER status, followed by PgR, CK17,
and CK5/6 statuses.
Her-2/neu status played a complex role in the dataset
variance, as it negatively aﬀected both hormone receptor
status (which was consistent with statistical correlations)and
basal CK status (as demonstrated only by factor analysis).
As previously reported, the basal-like phenotype and the
Her-2/neu expression are inversely correlated [9, 14, 65,
66], and it is likely that the nonbasal-like tumors include
a high prevalence of Her-2/neu ampliﬁed tumors [65]. In
this regard, it should be considered that the eﬀects of
Her-2/neu on the determination of the two clusters were
quite similar, being only slightly in favour of cluster II
(Figure 1(d)). Interestingly, Harris et al. reported that the
expressionofbasalmarkerswasstronglyassociated withHer-
2/neu+BCsnotresponding topreoperativetherapybasedon8 Pathology Research International
trastuzumab plus vinorelbine [53]. This underlines the need
tobetterverify theBC subsetsinwhich basal CKs, Her-2/neu
and hormone receptors could interact, in African and non-
African case series.
6.Conclusion
In the presently studied BC series from Central Sudan
the frequency of the tumors expressing basal CKs was
much higher than the frequencies reported for Caucasian
and African-American BC series, but it was comparable to
that found in BC series from East and West Africa [20,
25, 29, 33, 35, 51]. This suggests that the impact of the
tumors expressing basal CKs could be higher in sub-Saharan
African patients, a possibility that needs to be conﬁrmed by
additional studies in diﬀerent African populations. In Sudan
a higher impact of the tumors expressing basal CKs could
be ascribed to a variety of factors, including racial/genetic
factors, environmental and reproductive factors, population
structure, and sampling/referral bias. However, while an
early age of onset is one of the clinical characteristics
associated with BC expressing basal CKs, in our case series
basal CK-positive status was associated with higher grade
and hormone receptor-negative status, but not with age at
disease diagnosis and tumor size. This quite unexpected lack
of association might reﬂect a selective eﬀect of late disease
diagnosis. The most important factors for clusterization
in distinct BC subsets were ER status, followed by PgR,
CK17, and CK5/6 statuses. As in West Africa, the identiﬁed
clusters were in concordance with the gene expression-
based immunohistochemical subtypes deﬁned in Western
BC case series [5, 22, 26, 33], despite the diﬀerence in
patient population. However, the overall frequency of basal-
like subtype (ER−/PgR−/Her-2/neu−/basal CK+) was low
(10%, in Sudanese; 15.8%, in Nigerian), which was mainly
due to the reported markedly higher frequency of hormone
receptor positivity (ER: 64%; PgR: 67%; ER and/or ER: 75%
in Sudanese and ER+: 65.1%; PgR: 54.7% in Nigerian) as
compared to the other studies from Africa [33–37, 54].
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